{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:58:50Z","timestamp":1780894730440,"version":"3.54.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>LARC patients exhibit heterogeneity in their response to total neoadjuvant therapy (TNT). This study aims to screen and identify plasma biomarkers associated with treatment response to TNT in patients with locally advanced rectal cancer (LARC) to predict pathological complete response (pCR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Pre-treatment plasma RNA sequencing and functional annotation were performed in six patients with LARC (three pCR and three non-pCR) to identify differentially expressed genes (DEGs) associated with TNT response. The Olink\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Target 96 Oncology II panel was employed to validate a subset of DEGs at the protein level in 61 patients with LARC (20 pCR vs 41 non-pCR), 6 patients with rectal adenoma (RA), and 6 healthy participants. Correlations between pretreatment plasma differentially expressed proteins (DEPs), clinicopathological characteristics, and TNT-response in LARC patients were analyzed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to the non-pCR group, 365 DEGs were upregulated, and 198 were downregulated in the pCR group. These genes are involved in pathways related to cell growth and death, signal transduction, metabolism, the immune system, insulin secretion, mitophagy, and neutrophil extracellular trap formation. The transcriptomic analysis was conducted in a limited discovery cohort, and these DEGs identified should be interpreted with extreme caution due to the high risk of false discovery. Plasma levels of Fas ligand (FASLG), CD160, andLY6\/PLAUR domain containing 3 (LYPD3) in the pCR group were higher than those in the non-pCR group. Receiver operating characteristic (ROC) curve analysis showed that a multi-marker panel consisting of FASLG, CD160, and LYPD3 was superior to three individual indicators in predicting pCR, with an area under the curve (AUC) of 0.791 (95% CI, 0.668-0.885). According to the optimal cutoff value of the multi-marker panel, all LARC patients were stratified into high (n=34, 55.7%) and low (n=27, 44.3%) expression groups. Statistical analysis indicated that high expression group was associated with a higher proportion of EMVI-negative status and a higher pCR rate. High expression of multi-marker was associated with pCR in multivariate analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The multi-marker panel consisting of FASLG, CD160, and LYPD3 may serve as a candidate predictor of treatment response in LARC patients undergoing TNT, warranting further validation in larger, multicenter cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1799004","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:23:11Z","timestamp":1780892591000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["An exploratory integrative analysis of plasma transcriptomic and proteomic predictors of response to total neoadjuvant therapy in locally advanced rectal cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Zonglin","family":"Zhu","sequence":"first","affiliation":[{"name":"Medical Laboratory Center, Jinjiang Municipal Hospital (Shanghai Sixth People\u2019s Hospital Fujian)","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaizhen","family":"Wen","sequence":"additional","affiliation":[{"name":"Medical Laboratory Center, Jinjiang Municipal Hospital (Shanghai Sixth People\u2019s Hospital Fujian)","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoyi","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, Fujian Medical University Union Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Kang","sequence":"additional","affiliation":[{"name":"Medical Laboratory Center, Jinjiang Municipal Hospital (Shanghai Sixth People\u2019s Hospital Fujian)","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqing","family":"Chen","sequence":"additional","affiliation":[{"name":"Medical Laboratory Center, Jinjiang Municipal Hospital (Shanghai Sixth People\u2019s Hospital Fujian)","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Fujian Medical University Union Hospital","place":["Fuzhou Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, Fujian Medical University Union Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobo","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, Fujian Medical University Union Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s1470-2045(20)30555-6","article-title":"RAPIDO: a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00903","article-title":"The PROSPECT trial (Alliance N1048)","volume":"41","author":"Basch","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00079-6","article-title":"(UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00032","article-title":"OPRA: Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.3390\/jcm12082873","article-title":"Watch and wait approach for rectal cancer","volume":"12","author":"Cerdan-Santacruz","year":"2023","journal-title":"J Clin Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09192-0","article-title":"Avoiding unnecessary major rectal cancer surgery by implementing structural restaging and a watch-and-wait strategy after neoadjuvant radiochemotherapy","volume":"28","author":"Huisman","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000002290","article-title":"Rectal cancer approach strategies after neoadjuvant treatment - a systematic review and network meta-analysis","volume":"111","author":"Meng","year":"2025","journal-title":"Int J Surg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1361300","article-title":"Prediction of pathologic complete response to neoadjuvant chemoradiation in locally advanced rectal cancer","volume":"14","author":"Zhong","year":"2024","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyab274","article-title":"Circulating proteins and risk of pancreatic cancer: a case-subcohort study among Chinese adults","volume":"51","author":"Kartsonaki","year":"2022","journal-title":"Int J Epidemiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1038\/s41467-022-30569-0","article-title":"Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100931","article-title":"Multiplex immune profiling reveals the role of serum immune proteomics in predicting response to preoperative chemotherapy of gastric cancer","volume":"4","author":"Tang","year":"2023","journal-title":"Cell Rep Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.756902","article-title":"A linear discriminant analysis model based on the changes of 7 proteins in plasma predicts response to Anlotinib therapy in advanced non-small cell lung cancer patients","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40364-021-00266-z","article-title":"Targeted proteomics-derived biomarker profile develops a multi-protein classifier in liquid biopsies for early detection of esophageal squamous cell carcinoma from a population-based case-control study","volume":"9","author":"Yang","year":"2021","journal-title":"biomark Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33464","article-title":"Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma","volume":"148","author":"Yu","year":"2021","journal-title":"Int J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104515","article-title":"Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial","volume":"90","author":"Zhang","year":"2023","journal-title":"EBioMedicine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00384-024-04803-8","article-title":"Predicting treatment response and survival in rectal cancer: insights from 18 FDG-PET\/MRI post-neoadjuvant therapy","volume":"40","author":"Ferri","year":"2025","journal-title":"Int J Colorectal Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3390\/medicina61081449","article-title":"The role of baseline PET\/CT parameters in predicting treatment response in patients with locally advanced rectal cancer undergoing total neoadjuvant therapy","volume":"61","author":"Guren","year":"2025","journal-title":"Medicina"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-2997","article-title":"Rectal cancer: assessment of neoadjuvant chemoradiation outcome based on radiomics of multiparametric MRI","volume":"22","author":"Nie","year":"2016","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2025.112478","article-title":"Added value of 3D APT histogram analysis to DWI for predicting complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer","volume":"194","author":"Zhang","year":"2026","journal-title":"Eur J Radiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.70151","article-title":"Total neoadjuvant therapy with six versus four cycles of CAPOX in locally advanced rectal cancer: a real-world study","volume":"158","author":"Lan","year":"2026","journal-title":"Int J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/febs.14292","article-title":"Nonapoptotic functions of Fas\/CD95 in the immune response","volume":"285","author":"Guegan","year":"2018","journal-title":"FEBS J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.3390\/ijms22042177","article-title":"sFasL-the key to a riddle: immune responses in aging lung and disease","volume":"22","author":"Wallach-Dayan","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2011.02.003","article-title":"CD160: a unique activating NK cell receptor","volume":"138","author":"Le Bouteiller","year":"2011","journal-title":"Immunol Lett"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113694","article-title":"CD160 protein as a new therapeutic target in a battle against autoimmune, infectious and lifestyle diseases. Analysis of the structure, interactions and functions","volume":"224","author":"Piotrowska","year":"2021","journal-title":"Eur J Med Chem"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.795820","article-title":"LYPD3, a new biomarker and therapeutic target for acute myelogenous leukemia","volume":"13","author":"Hu","year":"2022","journal-title":"Front Genet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13062-023-00424-3","article-title":"LY6\/PLAUR domain containing 3 (LYPD3) maintains melanoma cell stemness and mediates an immunosuppressive microenvironment","volume":"18","author":"Hu","year":"2023","journal-title":"Biol Direct"},{"key":"B27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s43556-024-00189-9","article-title":"m6A-dependent mature miR-151-5p accelerates the Malignant process of HNSCC by targeting LYPD3","volume":"5","author":"Huang","year":"2024","journal-title":"Mol BioMed"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-23-1557","article-title":"Comprehensive analysis of exosome gene LYPD3 and prognosis\/immune cell infiltration in lung cancer","volume":"13","author":"Xin","year":"2024","journal-title":"Trans Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s10151-025-03180-w","article-title":"Increasing age, neural invasion, extramural vascular invasion, and short-course radiotherapy in locally advanced rectal cancer are associated with decreased tumor regression: a retrospective cohort study","volume":"29","author":"Johnsen","year":"2025","journal-title":"Techniques Coloproctology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-16962-1","article-title":"Predictors of pathologic non-response to neoadjuvant approaches in locally advanced rectal cancer","volume":"32","author":"Ng","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108738","article-title":"Prediction and validation of pathologic complete response for locally advanced rectal cancer under neoadjuvant chemoradiotherapy based on a novel predictor using interpretable machine learning","volume":"50","author":"Wang","year":"2024","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-1242","article-title":"ctDNA longitudinal analysis during total neoadjuvant therapy and nonoperative management for locally advanced rectal cancer: a biomarker study from the NOMINATE trial","volume":"31","author":"Akiyoshi","year":"2025","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad151","article-title":"Prognostic value of ctDNA detection in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy: a systematic review and meta-analysis","volume":"28","author":"Chang","year":"2023","journal-title":"Oncologist"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/po.21.00015","article-title":"Circulating miRNA signature predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer","volume":"5","author":"Wada","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003741","article-title":"Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: a prospective cohort study","volume":"18","author":"Wang","year":"2021","journal-title":"PloS Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c02436","article-title":"An enhanced cancer immunogenic cell death strategy: fibrate-oxaliplatin(IV) conjugates with modulating tumor immune microenvironment","volume":"68","author":"Liang","year":"2025","journal-title":"J Med Chem"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.3390\/cancers17233849","article-title":"Radiation-induced immune responses from the tumor microenvironment to systemic immunity","volume":"17","author":"Png","year":"2025","journal-title":"Cancers"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2026.113212","article-title":"Oxaliplatin-artesunate conjugate intensifies suppression on colorectal cancer by boosting antitumor immunity","volume":"277","author":"Tan","year":"2026","journal-title":"J Inorg Biochem"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1101\/2024.12.09.627497","article-title":"Effect of OASL on oxaliplatin-induced immunogenic cell death in gastric cancer via the cGAS-STING signaling pathway","volume":"12","author":"Zhang","year":"2025","journal-title":"Cell Death Discov"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/febs.70102","article-title":"Oxaliplatin accelerates immunogenic cell death by activating the cGAS\/STING\/TBK1\/IRF5 pathway in gastric cancer","volume":"292","author":"Zhao","year":"2025","journal-title":"FEBS J"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1799004\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:23:12Z","timestamp":1780892592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1799004\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":40,"alternative-id":["10.3389\/fonc.2026.1799004"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1799004","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"1799004"}}